Zaychenko G. V., Gorchakova N. O., Shumeiko O. V., Klymenko O. V.

LITERATURE REVIEWS

Scentific article

Iron is one of the most important macroelements in the body, which takes part in oxidation-reduction processes, and bioenergetics, and is a part of a number of enzymes. Iron deficiency is associated with food, pregnancy, fetal development, and some diseases. First of all, iron deficiency is established in iron-deficiency anemia, in addition to violations of biochemical indicators, immunological shifts and changes in the activity of vital organs and systems. The purpose of the study was to analyze the properties of iron and its preparations and their effects on the body. Object and research methods. On the topic of the study, a search and analysis of scientific literature was conducted in such databases as PubMed, Google Scholar, Scopus. Results and discussion. Iron reserves in the body are 3–6 g, the daily requirement is 20–30 mg. The need for iron increases in diseases with an increase in cardiac output, an increase in temperature, which requires taking drugs for oral and parenteral administration. In addition, if it is necessary to replenish iron reserves, it is recommended to take extracts from plants that contain it, such as common apricot (fruit pulp), blueberry fruits, beet roots, and common peach fruits. At the same time, it should be noted that iron can be in the oxidizing form of Fe2+ and the reduced form of Fe3+. It was determined that changes in iron metabolism and transport occur in pregnant women, which, in turn, is associated with changes in endothelial protective function. In modern methodological recommendations for the treatment of chronic heart failure, iron preparations are also included in the list of mandatory drugs, because in this condition, in addition to iron deficiency, disorders of the functions of the cardiovascular system have been found. A decrease in iron content has also been determined in various hypoxic conditions. Next they showed changes in iron metabolism in infectious diseases, such as COVID-19, tuberculosis, and HIV infection. In recent years, changes in iron content in neurodegenerative diseases have been noticed. Today, there are oral and parenteral iron preparations, but research is underway to create iron preparations that may have a more targeted effect and less toxicity. Conclusion. The current state of iron research in the functioning of vital organs and the occurrence of diseases presents scientists and clinicians with the task of involving new experimental and clinical methods to expand the understanding of the role of iron in pathobiochemical mechanisms, in pathological conditions, as well as the search for new approaches to treatment.

iron,transport mechanisms,iron-containing enzymes,iron deficiency,cardiovascular,infectious,neurodegenerative diseases.

1. Zaharova IN, Machneva EB. Korrektsiya defitsita zheleza: istoricheskie and sovremennyie aspektii. Semeynaya meditsina. 2014;1(57):142- 5.
2. Stepurko T, Semyhina T, Barska Y, Zakhozha V, Kharchenko N. Indeks zdorovia. Ukraine-2018: results of zahalnonatsionalnoho doslidzhennia [Internet]. eKMAIR; 2018 [cited 2022Aug 16]. Dostupno: http://ekmair.ukma.edu.ua/handle/123456789/18335. [in Ukrainian].
3. Vinogradova OP, Kuznetsova MN, Biryuchkova OA. Antianemic preparations in complex treatment of inflammatory diseases of small organs. Obstetrics and Gynecology. 2015;2:49-52.
4. Gromova OA, Torshin IY, Hadzhidis AK. Analiz mokulekyarnyih mehanizmov vozdeystviya zheleza (ii), medi, margantsa v patogeneze zhelezodefitsitnoy anemii. Clinical Pharmacology and Pharmacoeconomics. 2010;1:1-9.
5. Belovol AN, Knyazkova II. Ot metabolyzma zheleza – k voprosam pharmakolohycheskoi korrektsyy eho defytsyta [Internet]. Repository of Kharkiv National Medical University; 2015 [cited 2022Aug 16]. Dostupno: http://repo.knmu.edu.ua/handle/123456789/11697. [in Ukrainian].
6. Rumyantsev AG, Zaharova IN, Chernov VM, Tarasova IS, Zaplatnikov AL, Korovina NA, et al. Rasprostranennost zhelezodefitsitnyih sostoyaniy i faktorii, na nee vliyayuschie. Meditsinskiy sovet. 2015;6:62-6.
7. Baird-Gunning J, Bromley J. Correcting iron deficiency. Australian Prescriber. 2016;39(6):193-9. DOI: 10.18773/austprescr.2016.069.
8. Camaschella C. Iron-deficiency anemia. New England Journal of Medicine. 2015;372(19):1832-43. DOI: 10.1056/nejmra1401038.
9. Zaporozhan VN, Ancheva IA. Pharmacocorrection of endothelial dysfunction, occurred during comorbid deficiency anemia as a means of preventing complications of pregnancy and childbirth. HEALTH OF WOMEN. 2015;98(2):71-4. DOI: 10.15574/hw.2015.98.71.
10. Venkataramani V. Iron homeostasis and metabolism: Two sides of a coin. Ferroptosis: Mechanism and Diseases. 2021;1301:25-40. DOI: 10.1007/978-3-030-62026-4_3.
11. Magomedova AP, Lomova NA, Karapetyan TE, Amiraslanov EY. Latentnyiy defitsit zheleza and zhelezodefitsitnaya anemia beremennyih: posledstviya dlya materi i ploda, vozmozhnyie puti resheniya. Meditsinskiy sovet. 2021;4:170-3.
12. Gaillard R, Steegers EAP, Tiemeier H, Hofman A, Jaddoe VWV. Placental vascular dysfunction, fetal and childhood growth, and cardiovascular development. Circulation. 2013;128(20):2202-10. DOI: 10.1161/circulation aha.113.003881.
13. Arzoo S, Yousof S, Rahman J, Chowdhury S. Iron deficiency anemia in pregnancy: Intravenous iron sucrose versus oral iron sulfate. Bangladesh Journal of Obstetrics & Gynaecology. 2020;33(1):40-4. DOI: 10.3329/bjog. v33i1.43541.
14. Dalal M, Goyal R, Nanda S, Dahiya P, Dahiya K, Madan S. Oral versus intravenous iron for treatment of iron deficiency anemia in pregnancy: A randomized controlled trial. Indian Journal of Public Health Research & Development. 2018;9(6):4-6. DOI: 10.5958/0976- 5506.2018.00513.2.
15. Rogozińska E, Daru J, Nicolaides M, Amezcua-Prieto C, Robinson S, Wang R, et al. Iron preparations for women of reproductive age with iron deficiency anemia in pregnancy (Frida): A systematic review and network meta-analysis. The Lancet Haematology. 2021;8(7):503-12. DOI: 10.1016/s2352-3026(21) 00137-x.
16. Gopchuk OM. Iron deficiency anemia. Women’s Health. 2019;9(145):32-7.
17. Ganz T. Anemia of inflammation. New England Journal of Medicine. 2019;381(12):1148-57. DOI: 10.1056/nejmra1804281.
18. Liu Z, Sun R, Li J, Cheng W, Li L. Relations of anemia with the all-cause mortality and cardiovascular mortality in the general population: A meta-analysis. The American Journal of the Medical Sciences. 2019;358(3):191-9. DOI: 10.1016/j.amjms.2019.05.016.
19. Voronkov LG, Gorbachova VV, Liashenko AV, Gavrilenko TI, Mkhitaryan LS, Yakushko LV, et al. Clinical and instrumental characteristics of patients with chronic heart failure and reduced left ventricular ejection fraction without anemia, depending on the presence of iron deficiency. Ukrainian Journal of Cardiology. 2018;(6):101-8. DOI: 10.31928/1608-635x-2018.6.101108.
20. Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. European Heart Journal. 2014;36(11):657- 68. DOI: 10.1093/eurheartj/ehu385.
21. Hörl WH. Anemia management and mortality risk in chronic kidney disease. Nature Reviews Nephrology. 2013;9(5):291-301. DOI: 10.1038/nrneph. 2013.21.
22. Nikitin OD. Efektyvnist ta bezpeka zastosuvannia preparatu Sufer® v korektsii anemii u patsiientiv iz khronichnoiu nyrkovoiu destatnistiu. Ukrainskyi medychnyi chasopys. 2015;1:49-51. [in Ukrainian].
23. Ryndina NH, Kravchun PH, Mishyna MM. Pokaznyky ferokinezu yak prohnostychni markersy yakosti zhyttia anemichnykh khvorykh na khronichnu sertsevu dostastatnist, poiednanu z khronichnoiu khvoroboiu nyrok, ta yikh dynamika pid vlividom terapevtychnoi korektsii. Zdobutky klinichnoi i eksperimentalnoi medytsyny. 2013;2:152-4. [in Ukrainian].
24. Popovich MY. Iron deficiency anemia in Zakarpattya High mountain region: Relevance, diagnosis, and comprehensive treatment. Hematology Transfusiology Eastern Europe. 2020;(3):372-82. DOI: 10.34883/pi.2020. 6.3.023.
25. Musina NN, Saprina TV, Prohorenko TS, Zima AP, Prokonich DA. Specifics of inflammation parameters, ferrokinetics and structure of anemic syndrome in patients with diabetes. Conference Proceedings; 2021. p. 72-80. DOI: 10.14341/conf.22-25.09.21-378.
26. Taneri PE, Alejandro Gómez-Ochoa S, Llanaj E, Francis Raguindin P, Rojas LZ, Wyssmann BM, et al. Anemia and iron metabolism in COVID-19: A systematic review and meta-analysis. European journal of epidemiology. 2020;35(8):763-73. DOI: 10.1101/2020.06.04.20122267.
27. Borodulina EA, Yakovleva EV. Metabolism of iron in the organism and indicators reflecting changes in lung tuberculosis. Clinical laboratory diagnostics. 2016;65(2):149-54.
28. Shahandeh A, Bui BV, Finkelstein DI, Nguyen CT. Therapeutic applications of chelating drugs in iron metabolic disorders of the brain and retina. Journal of Neuroscience Research. 2020;98(10):1889-904. DOI: 10.1002/jnr.24685.
29. Shu W, Dunaief J. Potential treatment of retinal diseases with Iron Chelators. Pharmaceuticals. 2018;11(4):112. DOI: 10.3390/ph11040112.
30. Ward RJ, Zucca FA, Duyn JH, Crichton RR, Zecca L. The role of iron in Brain Aging and Neurodegenerative Disorders. The Lancet Neurology. 2014;13(10):1045-60. DOI: 10.1016/s1474-4422(14)70117-6.
31. Kostromitska IO, Misiurova AV, Propisnova VV. Kliniko-farmatsevtychnyi analiz Fe-vmisnykh preparativ, provedenyi na bazi apteky «Fetida» m. Kharkiv. Pharmacoeconomics in Ukraine: status and prospects. 2021 May 21;1:65-6. [in Ukrainian].
32. Nikravesh N, Borchard G, Hofmann H, Philipp E, Flühmann B, Wick P. Factors influencing safety and efficacy of intravenous ironcarbohydrate nanomedicines: From production to clinical practice. Nanomedicine: Nanotechnology, Biology and Medicine. 2020;26:102178. DOI: 10.1016/j.nano.2020.102178.

«Bulletin of problems biology and medicine» Issue 3 (166), 2022 year, 36-40 pages, index UDK 616.12.008.46:616.155.194.8

10.29254/2077-4214-2022-3-166-36-40